Ventripoint Diagnostics Ltd.
TSX VENTURE : VPT

Ventripoint Diagnostics Ltd.

December 03, 2014 07:42 ET

Ventripoint Heart Analysis System to be Exhibited at International Medical Conference in Vienna, Austria, and Grant of Stock Options

SEATTLE, WASHINGTON--(Marketwired - Dec. 3, 2014) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) is pleased to announce that the Company will be exhibiting at the EuroEcho-Imaging 2014 Congress from December 3-6, 2014. More than 3,500 participants who focus on echocardiology are expected to attend EuroEcho-Imaging 2014, which is the official annual meeting of the European Association of Cardiovascular Imaging, a registered branch of the European Society of Cardiology. Held in cooperation with the Austrian Working Group of Echocardiography, the Congress takes place in Vienna, Austria, at the Reed Messe Wien GmbH Congress Center.

"EuroEcho is always a great opportunity for us to meet with medical professionals, who use ultrasound daily for cardiac care", stated Jim Bodtke, Vice-President of Development and Clinical Affairs for Ventripoint. "With the latest clinical results from the L'hôpital Universitaire Necker-Enfants Malades in Paris (see news release November 5, 2014), we are looking forward to the discussions that will arise from this expanded use."

Other News

On November 19, 2014 the Company entered into a contract for investor relations consulting services with a Canadian investor relations firm. On November 24th the consulting firm was granted 375,000 stock options as part of its compensation. The options are exercisable at CDN$0.06 per common share until November 24, 2017. These options were subsequently exercised and 375,000 common shares were issued on November 27, 2014.

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. The VMS is the first cost-effective and accurate tool for measuring right ventricle heart function, and is approved for clinical use for selected cardiac indications in Canada, Europe and the United States. The Company has a suite of applications for all major heart diseases and imaging modalities, including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information